Cargando…

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

BACKGROUND: Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels. There a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niinivirta, Marjut, Georganaki, Maria, Enblad, Gunilla, Lindskog, Cecilia, Dimberg, Anna, Ullenhag, Gustav J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179003/ https://www.ncbi.nlm.nih.gov/pubmed/32321460 http://dx.doi.org/10.1186/s12885-020-06770-z

Ejemplares similares

Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2019)

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
por: van Hooren, Luuk, et al.
Publicado: (2016)

ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma
por: Huang, Hua, et al.
Publicado: (2021)

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
por: Gremel, Gabriela, et al.
Publicado: (2017)

ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype
por: Sheldon, Helen, et al.
Publicado: (2021)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
por: Georganaki, Maria, et al.
Publicado: (2018)

ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent
por: Kan, Anna, et al.
Publicado: (2018)

ELTD1—An Emerging Silent Actor in Cancer Drama Play
por: Sevastre, Ani-Simona, et al.
Publicado: (2021)

A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis
por: Masiero, Massimo, et al.
Publicado: (2013)

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
por: Gruenwald, Viktor, et al.
Publicado: (2010)

Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking ELTD1
por: Xiao, Jinfeng, et al.
Publicado: (2012)

ELTD1 promotes invasion and metastasis by activating MMP2 in colorectal cancer
por: Sun, Jiawei, et al.
Publicado: (2021)

ELTD1 as a multi-focal target for malignant gliomas: preclinical studies
por: Zalles, Michelle, et al.
Publicado: (2021)

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
por: Brossa, Alessia, et al.
Publicado: (2018)

Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma
por: Mizuno, Ryuichi, et al.
Publicado: (2017)

ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile
por: Favara, David M., et al.
Publicado: (2019)

Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling
por: Favara, David M., et al.
Publicado: (2021)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
por: Fiorio Pla, Alessandra, et al.
Publicado: (2014)

Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma
por: Lai, Silvia, et al.
Publicado: (2020)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
por: Eriksson, E, et al.
Publicado: (2017)

Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects
por: Huang, Dan, et al.
Publicado: (2023)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
por: Dornbusch, Juana, et al.
Publicado: (2013)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model
por: Zalles, Michelle, et al.
Publicado: (2019)

Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model()()
por: Zalles, Michelle, et al.
Publicado: (2020)

Adhesion G protein-coupled receptor, ELTD1, is a potential therapeutic target for retinoblastoma migration and invasion
por: Guihurt Santiago, Jonathan, et al.
Publicado: (2021)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Cancer treatment of today in view of the Nobel Prize
por: Ullenhag, Gustav
Publicado: (2018)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007
por: Zalles, Michelle, et al.
Publicado: (2021)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
por: Georganaki, Maria, et al.
Publicado: (2020)

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
por: Small, Jeffrey, et al.
Publicado: (2017)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i33cl3922b0c52i2944d2d7ob5